Hayden Eric Y, Conovaloff Joseph L, Mason Ashley, Bitan Gal, Teplow David B
Department of Neurology, David Geffen School of Medicine, and Molecular Biology Institute and Brain Research Institute, University of California, Los Angeles, CA 90095, United States.
Department of Neurology, David Geffen School of Medicine, and Molecular Biology Institute and Brain Research Institute, University of California, Los Angeles, CA 90095, United States.
Anal Biochem. 2017 Feb 1;518:78-85. doi: 10.1016/j.ab.2016.10.026. Epub 2016 Oct 31.
Evidence suggests that amyloid β-protein (Aβ) oligomers may be seminal pathogenic agents in Alzheimer's disease (AD). If so, developing oligomer-targeted therapeutics requires an understanding of oligomer structure. This has been difficult due to the instability of these non-covalently associated Aβ assemblies. We previously used rapid, zero-length, in situ chemical cross-linking to stabilize oligomers of Aβ40. These enabled us to isolate pure, stable populations of dimers, trimers, and tetramers and to determine their structure-activity relationships. However, equivalent methods applied to Aβ42 did not produce stable oligomers. We report here that the use of an Aβ42 homologue, [F10, Y42]Aβ42, coupled with sequential denaturation/dissociation and gel electrophoresis procedures, provides the means to produce highly pure, stable populations of oligomers of sizes ranging from dimer through dodecamer that are suitable for structure-activity relationship determination.
有证据表明,淀粉样β蛋白(Aβ)寡聚体可能是阿尔茨海默病(AD)的主要致病因子。如果是这样,开发针对寡聚体的疗法需要了解寡聚体结构。由于这些非共价结合的Aβ聚集体不稳定,这一点一直很难做到。我们之前使用快速、零长度、原位化学交联来稳定Aβ40的寡聚体。这使我们能够分离出纯的、稳定的二聚体、三聚体和四聚体群体,并确定它们的构效关系。然而,应用于Aβ42的等效方法并未产生稳定的寡聚体。我们在此报告,使用Aβ42同系物[F10, Y42]Aβ42,结合顺序变性/解离和凝胶电泳程序,提供了产生高度纯净、稳定的寡聚体群体的方法,这些寡聚体大小从二聚体到十二聚体不等,适用于构效关系的确定。